Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
354.00 INR | -0.56% |
|
+3.48% | -10.92% |
06-09 | Jyothy Labs Limited, Q4 2025 Earnings Call, May 12, 2025 | |
05-12 | Jyothy Labs Limited Reports Earnings Results for the Full Year Ended March 31, 2025 | CI |
Summary: Jyothy Labs Limited
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Highlights: Jyothy Labs Limited
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses: Jyothy Labs Limited
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 34.26 and 33.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings Chart: Jyothy Labs Limited
Source: Surperformance
ESG chart: Jyothy Labs Limited
Source: MSCI
Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
---|---|---|---|---|---|
- | - | 1.52B | |||
45.98B | |||||
24.15B | |||||
15.6B | |||||
4.6B | |||||
3.7B | |||||
2.76B | |||||
Average | 14.04B | ||||
Weighted average by Cap. |
Investor (Composite)
-
Trader (Composite)
ESG MSCI
BB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
-
Net Margin
Financial Health (Composite)
-
Valuation
P/E
EV/Revenue
-
EV/EBITDA
-
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- JYOTHYLAB Stock
- Ratings Jyothy Labs Limited
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition